Safety and efficacy of the oral CXCR4 inhibitor X4P-001+axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment Article

Web of Science: 000491295503234
International Collaboration

Cited authors

  • McDermott, D. F.; Vaishampayan, U.; Matrana, M.; Rha, S. Y.; Saavedra, A. Zurita; Ho, T.; Keam, B.; Lee, J-L.; Joseph, R.; Ali, S.; Stadler, W.; Haas, N. B.; Sundararajan, S.; Park, S. H.; Mowat, R.; Picus, J.; Dudek, A. Z.; Zakharia, Y.; Gan, L.; Atkins, M. B.

Publication date

  • 2019

Published in

International Standard Serial Number (ISSN)

  • 0923-7534


  • 30